PURA – Puration Views Canopy Growth Sports Beverage Acquisition Targeting $50 Billion Market As Good News For PURA
Dallas, TX – October 8, 2019 — OTC PR WIRE – Puration, Inc. (USOTC: PURA) today highlighted Canopy Growth’s acquisition of sports beverage maker BioSteel Sports Nutrition. PURA introduced its own CBD infused sports drink in 2017 reporting its first million in sales in 2018 and targeting $4 million in sales this year in 2019. PURA management views Canopy Growth’s entrance into the $50 billion sports nutrition market as a validation of PURA’s strategic direction with its own EVERx CBD Sports Water. Aurora Cannabis also recently entered the sector through a deal with the UFC. PURA management believes PURA is a step ahead of the big money cannabis players with its EVERx experience. “EVERx has refined its formula based on a U.S. Patented Cannabis Extraction Process multiple times since its launch in reaction to live production and marketing experiences that neither Canopy nor Aurora have had the opportunity yet to experience for themselves,” said PURA CEO Brian Shibley. EVERx has also had the opportunity to establish brand recognition in the sports nutrition market largely through its ongoing marketing campaign with Arnold Schwarzenegger’s Worldwide Sports Festival. Shibley added, “Aurora and Canopy’s entrance into the sports nutrition market validates CBD as valuable to fitness enthusiast and athletes. Their entrance is likely to bring even more attention to CBD as a sports nutrition additive bringing more fitness enthusiasts and athletes looking for a beverage and that’s likely to be good for EVERx sales.”
The Canopy acquisition is featured today in an article from Motley Fool:
PURA Goldman Small Cap Research Coverage
On Wednesday, last week, Goldman Small Cap Research issued an “Alert” follow-up to its recent Research Analyst Report issued on PURA published on September 25th, 2019 (report link below). The Research Analyst Report was triggered by the previously mentioned CBD Beverage Industry Survey conducted on behalf of PURA. The “Alert” issued last Wednesday is a confirmation of the original investment recommendations and highlights investment new opportunities (alert link below).
To see the full trade alert issued today, follow the link below:
To see the full Analyst Report issued last week, follow the link below:
For more information on Puration, visit http://www.purationinc.com
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.